#SupplementIndustry – Chris Paulk

Last week, we made a commitment: to tell you what the research on muscadine actually shows, including where it stops. This week, we’re following through.

The Banini study is the most directly relevant published human trial on muscadine and metabolic markers. Here’s exactly what it was, what it found, and where its limits lie.

The Study at a Glance

Banini AE, Boyd LC, Allen JC, Allen HG, and Sauls DL. “Muscadine grape products intake, diet and blood constituents of non-diabetic and type 2 diabetic subjects.” Nutrition, 2006; 22(11–12):1137–1145. North Carolina State University.

Element	Detail
Study	Banini AE et al., Nutrition 2006; 22(11–12):1137–1145
Institution	North Carolina State University, Raleigh, NC
Design	Non-randomized, non-blinded dietary intervention; 28 days
Population	Type 2 diabetic subjects (assigned to MJ, MW, or Dz-W) and non-diabetic subjects (juice only)
Intervention	150 mL/day of muscadine grape juice (MJ), muscadine grape wine (MW), or dealcoholized muscadine grape wine (Dz-W) with meals
Primary outcomes	Glycemic indices, blood glucose, insulin, glycated hemoglobin (HbA1c), lipid profile, blood constituents
Key findings	Diabetics given MW and Dz-W showed lower blood glucose, insulin, and HbA1c vs. diabetics given MJ. Dz-W group: fasting blood insulin reduced; glucose:insulin ratio improved from 8.5 to 13.1. MJ and MW did not differ in fasting glucose, insulin, or HbA1c in the non-diabetic group.
Study limitation	Non-diabetic group received juice only — no wine or Dz-W arm. No placebo control. Cannot compare non-diabetic outcomes to diabetic outcomes across product types.

What It Found

The most meaningful findings came from Type 2 diabetic subjects assigned to muscadine wine and dealcoholized muscadine wine. Compared with diabetics given muscadine juice, those groups had lower blood glucose, insulin, and glycated hemoglobin levels over the 28-day period.

The dealcoholized wine group — the arm most relevant to a supplement context, since alcohol is removed — showed a specific improvement in fasting blood insulin levels. The fasting blood glucose-to-insulin ratio rose from 8.5 to 13.1 over the intervention period. The researchers noted that a ratio below 7 is considered predictive of insulin resistance; the published data showed movement away from that threshold in the T2D group over 28 days.

These are real findings from a real peer-reviewed study in a population where metabolic markers matter most.

What It Doesn’t Show

Here is where we’re going to be direct, because this is where ingredient marketing most often goes wrong.

The non-diabetic subjects in this study received only muscadine juice. There was no wine or dealcoholized wine arm for healthy subjects, and no placebo control for that group. You cannot draw conclusions about muscadine’s effect on healthy adults’ metabolic markers from this study design.

The intervention used whole beverage forms — 150 mL of juice, wine, or dealcoholized wine per day. This is not the same as a standardized extract powder or capsule. The polyphenol dose, bioavailability, and matrix context of a beverage differ from those of an encapsulated ingredient. Extrapolating these findings to a capsule product requires additional research.

28 days is a short intervention window. These findings are a signal worth taking seriously, not a conclusion about long-term metabolic outcomes.

This was not a randomized, blinded, placebo-controlled trial — the design most likely to produce generalizable results. The findings are meaningful and peer-reviewed, but the study design has limitations that should inform how confidently you cite it.

Why This Still Matters for Formulators

Here’s why it still matters.

Many metabolic health ingredients have limited or no peer-reviewed human research. Their evidence base often rests on mechanistic rationale — in vitro studies showing that a compound interacts with a relevant pathway in cell culture, which is a long way from a human outcome. The Banini study, with its clearly stated limitations, still places muscadine in a category most competing ingredients cannot enter.

This research also holds up when a retailer or practitioner asks the right question — not “what does your marketing say?” but “what does your best published human study actually show?” We can answer that with a citation, a methodology, and an honest account of what was and wasn’t found. That’s a more defensible position than most suppliers in this category can offer.

The Right Application

Given what this study used, the MPC ingredient form most directly relevant to this research context is Muscadine Juice Concentrate — the beverage-form polyphenol delivery that most closely mirrors what was studied. It is appropriate for liquid supplement applications and functional beverage formulations.

Muscadine Skin/Seed Powder — our encapsulated ingredient form — provides the same phytochemical profile in capsule or tablet applications. It is a non-soluble powder, appropriate for encapsulation, not for beverage blending. The phytochemical case for that form is strong; the direct clinical link to the Banini study is more attenuated, and we will not overstate it.

If your R&D team wants to review the full Banini citation, methodology, and published abstract, contact us and we’ll send them directly. We’d rather put the actual study in front of your team than a polished summary.

Next Week

The series moves to June’s theme: Skin Health / Beauty From Within. We’ll cover Muscadine Seed Oil and Skin Extract — two ingredients with a genuinely differentiated story for cosmetic formulators and ingestible beauty brands. If you want to be ready for that conversation, visit muscadineproducts.com to request a sample or technical documentation.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Research references are cited for informational and educational purposes. The Banini study was conducted in a Type 2 diabetic population using whole beverage forms of muscadine; findings should not be generalized to healthy populations or encapsulated ingredient forms without additional research. Formulators should consult qualified regulatory counsel before establishing label claims for finished consumer products. Muscadine Products Corporation • Wray, Georgia • muscadineproducts.com

If you’ve spent any time sourcing ingredients for the metabolic health category, you already know the problem.

The shelves — and the trade show floors — are full of formulas built on blood sugar and insulin sensitivity claims. Most of them are backed by in vitro studies, animal model data, or industry-sponsored trials that haven’t been independently replicated. A growing number of retailers, practitioners, and sophisticated consumers have noticed. They’re asking harder questions. And brands that built their metabolic formulas on overclaimed evidence are finding those questions uncomfortable to answer.

We’re launching this content series — Formulate with Purpose — because we think the ingredient sourcing conversation in this industry deserves more honesty than it usually gets. Starting here, in one of the categories where that problem is most visible.

What We Mean by Credibility

In the metabolic health ingredient market, credibility has two components that most ingredient marketing conflates: the science and the source.

The science question is: has this ingredient been studied in peer-reviewed human research, with a clearly defined study population, by researchers who weren’t paid by the ingredient supplier? And if so, what did those studies actually find — not what does the marketing summary claim they found?

The source question is: do you know where this ingredient was grown, how it was processed, and who handled it between the farm and your production facility? Or did you buy it from a broker who bought it from a distributor who sourced it from an overseas supplier whose growing practices you’ve never seen?

Both of those questions have uncomfortable answers for a lot of the metabolic health ingredient market right now. We’d rather address that directly than pretend otherwise.

The Muscadine Research: What It Shows and What It Doesn’t

Muscadine (Vitis rotundifolia) has been studied in peer-reviewed human research in a metabolic context. The most directly relevant published study — Banini et al. (Nutrition, 2006) — examined the effects of muscadine grape products on glycemic indices, lipid profiles, and blood constituents over a 28-day period.

The study population matters, and we’re going to tell you exactly what it was: Type 2 diabetic subjects, alongside a non-diabetic comparison group. The researchers observed improvements in several metabolic markers among diabetic subjects who consumed muscadine wine or dealcoholized wine, compared with those given muscadine juice.

That is an interesting finding in a disease-specific population using muscadine in beverage form. It is not evidence that a muscadine extract capsule will improve blood sugar in healthy adults, and we won’t frame it that way. We think you’d respect us less if we did.

What this research does tell us — honestly — is that muscadine polyphenols have been studied in a peer-reviewed human trial in a metabolic context. That puts muscadine in a different tier than metabolic ingredients whose entire evidence base is a cell culture study.

The Phytochemical Case

Muscadine contains ellagic acid, oligomeric proanthocyanidins (OPCs), resveratrol, and anthocyanins in documented concentrations. These compounds have been studied in nutritional science for their potential roles in supporting various physiological functions.*

The ellagic acid concentration in muscadine skin and seed is notably high compared to most vinifera-derived comparators — a documented analytical fact, not a marketing claim. The OPC subfraction profile is structurally distinct from conventional grape seed or pine bark extract, which affects both the mechanism and bioavailability questions that your R&D team should be asking.

We’ll go deeper on the compound-level science in the weeks ahead. For now, the point is this: the phytochemical profile gives formulators a mechanistic rationale for why muscadine is worth investigating. It is not, by itself, a finished clinical credential for a label claim.

The Sourcing Case

Here is where we can speak without any qualification at all.

Paulk Vineyards grows muscadines on more than 800 acres of estate farmland in Wray, Georgia in Irwin County. Seventh-generation family farming. Muscadine Products Corporation produces all of the ingredients on our family farm. We own the land, we run the harvest, and we process the fruit on-site. There are no brokers between the vine and the ingredient lot. This is family-owned & operated.

Every production run carries full lot traceability. We can document the growing practices, the harvest date, the processing method, and the analytical results for every lot we ship. If your QA team asks where the ingredient came from, we can show them, not just tell them.

In a market where most botanical ingredients pass through three or four broker hands before they reach a production facility — with origin documentation that ranges from thin to nonexistent — a fully traceable, domestic, estate-grown supply chain is not a small thing. It’s increasingly the difference between a brand story that holds up and one that doesn’t.

What’s Coming in This Series

Every week, this series will cover one topic relevant to formulators and ingredient buyers sourcing in the functional nutrition market: published research, sourcing frameworks, ingredient science, application guidance, and supply chain considerations.

We will tell you what the research shows. We will also tell you what it doesn’t show. We think that combination — honest science plus traceable sourcing — is what the market actually needs more of right now.

If you’d like to request a sample or review technical documentation, visit muscadineproducts.com. We’ll start with the data.

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Research references are cited for informational and educational purposes. Clinical research findings reflect what was observed in the referenced study population and do not guarantee individual results. Formulators should consult qualified regulatory counsel before establishing label claims for finished consumer products. Muscadine Products Corporation • Wray, Georgia • muscadineproducts.com

Tag: #SupplementIndustry

What the Banini Study Actually Shows — and What It Doesn’t